Skip to main content
Fig. 6 | Experimental Hematology & Oncology

Fig. 6

From: Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia

Fig. 6

Moderate levels of cross-resistance and substantial sensitization towards venetoclax in pinometostat-resistant KMT2A-rearranged ALL cells. A. Drug response curves for prednisolone, dexamethasone, vincristine, daunorubicin, cladribine, cytarabine, and L-asparaginase as determined by 4-day MTT assays in SEM and SEMPINO_RES cells with n = 4 biological replicates, each comprising n = 3 technical replicates, and presented as the mean ± standard error of the mean (SEM). B. Comparison of the IC50 in SEM and SEMPINO_RES cells for a total of 679 compounds tested in drug library screens. C. Showing the top 10 agents with the highest fold-changes in IC50 values in SEMPINO_RES as compared to SEM, indicating enhanced resistance in SEMPINO_RES cells. D. The top 10 drugs with the lowest fold-changes in IC50 values in SEMPINO_RES as compared to SEM, indicating enhanced sensitivity in SEMPINO_RES cells. E. Drug response curves for venetoclax as determined by 4-day MTT assays in indicated cell lines models (in duplicate), presented as the mean ± standard error of the mean (SEM)

Back to article page